首页 > 最新文献

Clinical & Translational Oncology最新文献

英文 中文
Prognostic value of systemic inflammation response indexes obtained from the complete blood count in patients treated for advanced ovarian carcinoma in front line. 通过全血细胞计数获得的晚期卵巢癌前线治疗患者全身炎症反应指数的预后价值。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-12-01 Epub Date: 2024-06-10 DOI: 10.1007/s12094-024-03523-3
Jaime Espinós, José Manuel Aramendía, Antonio González-Martín, Marta Santisteban, Luisa Sánchez, Ángel Vizcay, José Ángel Mínguez, Juan Luis Alcázar

Objective: Various systemic inflammation response indexes (SIRI) have repeatedly been described as prognostic factors in ovarian cancer. They have not been validated in prospective trials and published results are sometimes contradictory. We aimed to explore their role in a cohort of patients diagnosed with stage III and IV ovarian cancer treated at our institution.

Methods: We retrospectively examined the prognostic influence of the neutrophil-to-lymphocyte ratio (NLR), the platelet-to-lymphocyte ratio (PLR), the monocyte-to-lymphocyte ratio (MLR), the red cell distribution width (RDW), and the mean platelet volume (MPV).

Results: A total of 77 patients were analyzed. NLR > 2.243 at diagnosis, NLR before primary surgery, MLR at diagnosis, PLR > 289.1 at diagnosis, and PLR at diagnosis were significant in univariate Cox regression for progression-free survival, but none of them retained their significance in the multivariate Cox regression analysis. For overall survival, NLR >  = 2.53 at diagnosis, MLR >  = 0.245 at diagnosis, and PLR >  = 198.3 at diagnosis resulted significant in univariate COX regression; only PLR >  = 198.3 at diagnosis retained its significance in the multivariate analysis.

Conclusion: In our cohort, PLR >  = 198.3 was an independent prognostic factor for worse OS. The definitive role of SIRI in ovarian cancer has not yet been established. If their value as prognostic factors could finally be established, they would become a simple and economical method to predict prognosis in patients with advanced ovarian cancer. Therefore, it is time to conduct prospective, multicenter studies with larger samples to definitively establish its role in ovarian cancer, if any.

目的:各种全身炎症反应指数(SIRI)被反复描述为卵巢癌的预后因素。这些指标尚未在前瞻性试验中得到验证,公布的结果有时也相互矛盾。我们的目的是在本院治疗的一组 III 期和 IV 期卵巢癌患者中探讨它们的作用:我们回顾性研究了中性粒细胞与淋巴细胞比值(NLR)、血小板与淋巴细胞比值(PLR)、单核细胞与淋巴细胞比值(MLR)、红细胞分布宽度(RDW)和平均血小板体积(MPV)对预后的影响:共对 77 名患者进行了分析。诊断时的 NLR > 2.243、初次手术前的 NLR、诊断时的 MLR、诊断时的 PLR > 289.1 和诊断时的 PLR 在无进展生存期的单变量 Cox 回归分析中具有显著性,但在多变量 Cox 回归分析中均不具有显著性。就总生存率而言,诊断时的 NLR > = 2.53、诊断时的 MLR > = 0.245 和诊断时的 PLR > = 198.3 在单变量 COX 回归中具有显著性;只有诊断时的 PLR > = 198.3 在多变量分析中保持显著性:在我们的队列中,PLR > = 198.3 是导致 OS 恶化的独立预后因素。SIRI在卵巢癌中的确切作用尚未确定。如果它们作为预后因素的价值最终得以确定,那么它们将成为预测晚期卵巢癌患者预后的一种简单而经济的方法。因此,现在应该开展前瞻性、多中心、大样本的研究,以最终确定 SIRI 在卵巢癌中的作用(如果有的话)。
{"title":"Prognostic value of systemic inflammation response indexes obtained from the complete blood count in patients treated for advanced ovarian carcinoma in front line.","authors":"Jaime Espinós, José Manuel Aramendía, Antonio González-Martín, Marta Santisteban, Luisa Sánchez, Ángel Vizcay, José Ángel Mínguez, Juan Luis Alcázar","doi":"10.1007/s12094-024-03523-3","DOIUrl":"10.1007/s12094-024-03523-3","url":null,"abstract":"<p><strong>Objective: </strong>Various systemic inflammation response indexes (SIRI) have repeatedly been described as prognostic factors in ovarian cancer. They have not been validated in prospective trials and published results are sometimes contradictory. We aimed to explore their role in a cohort of patients diagnosed with stage III and IV ovarian cancer treated at our institution.</p><p><strong>Methods: </strong>We retrospectively examined the prognostic influence of the neutrophil-to-lymphocyte ratio (NLR), the platelet-to-lymphocyte ratio (PLR), the monocyte-to-lymphocyte ratio (MLR), the red cell distribution width (RDW), and the mean platelet volume (MPV).</p><p><strong>Results: </strong>A total of 77 patients were analyzed. NLR > 2.243 at diagnosis, NLR before primary surgery, MLR at diagnosis, PLR > 289.1 at diagnosis, and PLR at diagnosis were significant in univariate Cox regression for progression-free survival, but none of them retained their significance in the multivariate Cox regression analysis. For overall survival, NLR >  = 2.53 at diagnosis, MLR >  = 0.245 at diagnosis, and PLR >  = 198.3 at diagnosis resulted significant in univariate COX regression; only PLR >  = 198.3 at diagnosis retained its significance in the multivariate analysis.</p><p><strong>Conclusion: </strong>In our cohort, PLR >  = 198.3 was an independent prognostic factor for worse OS. The definitive role of SIRI in ovarian cancer has not yet been established. If their value as prognostic factors could finally be established, they would become a simple and economical method to predict prognosis in patients with advanced ovarian cancer. Therefore, it is time to conduct prospective, multicenter studies with larger samples to definitively establish its role in ovarian cancer, if any.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"3211-3217"},"PeriodicalIF":2.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11564363/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141297169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identification of SMC2 and SMC4 as prognostic markers in breast cancer through bioinformatics analysis. 通过生物信息学分析确定乳腺癌预后标志物 SMC2 和 SMC4。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-12-01 Epub Date: 2024-05-21 DOI: 10.1007/s12094-024-03521-5
Lili Pei, Yu Li, Hao Gu, Siqi Wang, Wenhao Wu, Siyi Fan, Xiao Shi, Xinxin Si

Background: Breast cancer (BRCA) is one of the most common malignant tumors. The structural maintenance of chromosome (SMC) gene family has been shown to play an important role in human cancers. However, the role of SMC families in BRCA is unclear. This study aimed to explore the role and potential clinical value of whole SMCs in BRCA.

Methods: TIMER and UALCAN database were used to analysis the expression level. Genetic variations were analyzed by cBioPortal. Promoter methylation and protein level were analyzed by UCLCAN. GO and KEGG were analyzed by Metascape database. Prognostic value of SMCs was analyzed by Kaplan-Meier and multivariate cox regression analyses. Immune infiltration analysis was conducted by CIBERSORT. Immunotherapy outcome prediction was conducted by Cancer Immunome Atlas. Targeted drug therapy outcome prediction was taken by GDSC and R language. The cell viability was tested by CCK8 and migration was tested by wound healing assay. Xenograft model was used to investigate the in vivo role of SMC2.

Results: Expression levels of SMC1A, SMC2, SMC4, SMC5 and SMC6 mRNA were increased in BRCA tissues, and negatively correlated with promoter methylation. Overexpression of SMC2 and SMC4 was negatively correlated with survival. Function of SMCs family regulatory genes was mainly related to ATPase activity. Expression of most SMCs was negatively correlated with immunotherapy and drug therapy outcomes. Interfere SMC2 and SMC4 decreased IC50 values of 5-fluorouracil and oxaliplatin and inhibited the migration of MCF7 cells. Tumor growth and weights were significantly decreased in si-SMC2 groups.

Conclusions: Combined bioinformatics and clinical specimen analysis verified SMC2 and SMC4 as independent prognostic factors in BRCA, suggesting their significance for the diagnosis and treatment of BRCA.

背景:乳腺癌(BRCA)是最常见的恶性肿瘤之一:乳腺癌(BRCA)是最常见的恶性肿瘤之一。染色体结构维护(SMC)基因家族已被证明在人类癌症中扮演重要角色。然而,SMC 家族在 BRCA 中的作用尚不清楚。本研究旨在探索整个 SMC 在 BRCA 中的作用和潜在临床价值:方法:使用 TIMER 和 UALCAN 数据库分析表达水平。遗传变异通过 cBioPortal 进行分析。启动子甲基化和蛋白质水平由 UCLCAN 分析。Metascape数据库分析了GO和KEGG。通过Kaplan-Meier和多变量Cox回归分析对SMCs的预后价值进行分析。免疫浸润分析由 CIBERSORT 进行。免疫治疗结果预测由癌症免疫组图谱(Cancer Immunome Atlas)进行。靶向药物治疗结果预测采用 GDSC 和 R 语言。用CCK8检测细胞活力,用伤口愈合试验检测细胞迁移。使用异种移植模型研究 SMC2 在体内的作用:结果:SMC1A、SMC2、SMC4、SMC5 和 SMC6 mRNA 在 BRCA 组织中的表达水平升高,并与启动子甲基化呈负相关。SMC2 和 SMC4 的过表达与存活率呈负相关。SMCs 家族调控基因的功能主要与 ATPase 活性有关。大多数SMCs的表达与免疫治疗和药物治疗的结果呈负相关。干扰SMC2和SMC4可降低5-氟尿嘧啶和奥沙利铂的IC50值,并抑制MCF7细胞的迁移。Si-SMC2组的肿瘤生长和重量明显减少:结论:结合生物信息学和临床标本分析验证了SMC2和SMC4是BRCA的独立预后因素,这表明它们对BRCA的诊断和治疗具有重要意义。
{"title":"Identification of SMC2 and SMC4 as prognostic markers in breast cancer through bioinformatics analysis.","authors":"Lili Pei, Yu Li, Hao Gu, Siqi Wang, Wenhao Wu, Siyi Fan, Xiao Shi, Xinxin Si","doi":"10.1007/s12094-024-03521-5","DOIUrl":"10.1007/s12094-024-03521-5","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer (BRCA) is one of the most common malignant tumors. The structural maintenance of chromosome (SMC) gene family has been shown to play an important role in human cancers. However, the role of SMC families in BRCA is unclear. This study aimed to explore the role and potential clinical value of whole SMCs in BRCA.</p><p><strong>Methods: </strong>TIMER and UALCAN database were used to analysis the expression level. Genetic variations were analyzed by cBioPortal. Promoter methylation and protein level were analyzed by UCLCAN. GO and KEGG were analyzed by Metascape database. Prognostic value of SMCs was analyzed by Kaplan-Meier and multivariate cox regression analyses. Immune infiltration analysis was conducted by CIBERSORT. Immunotherapy outcome prediction was conducted by Cancer Immunome Atlas. Targeted drug therapy outcome prediction was taken by GDSC and R language. The cell viability was tested by CCK8 and migration was tested by wound healing assay. Xenograft model was used to investigate the in vivo role of SMC2.</p><p><strong>Results: </strong>Expression levels of SMC1A, SMC2, SMC4, SMC5 and SMC6 mRNA were increased in BRCA tissues, and negatively correlated with promoter methylation. Overexpression of SMC2 and SMC4 was negatively correlated with survival. Function of SMCs family regulatory genes was mainly related to ATPase activity. Expression of most SMCs was negatively correlated with immunotherapy and drug therapy outcomes. Interfere SMC2 and SMC4 decreased IC<sub>50</sub> values of 5-fluorouracil and oxaliplatin and inhibited the migration of MCF7 cells. Tumor growth and weights were significantly decreased in si-SMC2 groups.</p><p><strong>Conclusions: </strong>Combined bioinformatics and clinical specimen analysis verified SMC2 and SMC4 as independent prognostic factors in BRCA, suggesting their significance for the diagnosis and treatment of BRCA.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"2952-2965"},"PeriodicalIF":2.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141077254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Early diagnostic value of ECT whole-body bone imaging combined with PINP and β-CTX for bone metastasis of lung cancer. ECT 全身骨成像结合 PINP 和 β-CTX 对肺癌骨转移的早期诊断价值。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-12-01 Epub Date: 2024-05-30 DOI: 10.1007/s12094-024-03475-8
Meiying Jiang, Qiyun Yu, Haitao Mei, Yingchao Jian, Rong Xu

Objective: This research was aimed at investigating the early diagnostic value of emission computed tomograph (ECT) whole-body bone imaging combined with PINP and β-CTX for bone metastasis of lung cancer.

Methods: Case data of 86 lung cancer patients were categorized into lung cancer with bone metastasis (LCWBM, 46 cases) and lung cancer without bone metastasis (LCWOBM, 40 cases) groups according to the presence or absence of bone metastasis. Patients' general information were collected. ECT whole-body bone imaging was used to detect bone metastases and the grading of the extent of disease (EOD) in both groups, and electrochemiluminescence was utilized to detect the serum levels of PINP and β-CTX. Spearman correlation analysis was employed to evaluate the correlation between EOD grading and PINP and β-CTX levels. Logistic univariate and multivariate regression was implemented to analyze the risk factors of bone metastasis of lung cancer. Receiver operating characteristic (ROC) curve was applied to analyze the diagnostic efficacy of the single test of ECT whole-body bone imaging, PINP, or β-CTX and the combination of the three tests.

Results: The differences in pathological type, clinical stage and EOD grading, the number of positive ECT cases, and the expression levels of PINP and β-CTX between the LCWBM and LCWOBM groups were statistically significant. In LCWBM patients with different EOD grading, the trends of the expression of PINP and β-CTX were grade 3 > grade 2 > grade 1 and grade 0. Further correlation analyses revealed that EOD grading showed a significant positive correlation with the PINP and β-CTX expression levels. Univariate logistic regression analysis demonstrated that adenocarcinoma, TNM stage IV, ECT positivity, and high expression of PINP and β-CTX were associated with bone metastasis of lung cancer, and multivariate logistic regression analysis indicated that ECT positivity, high expression of PINP and β-CTX were independent risk factors for bone metastasis of lung cancer. The area under the curve (AUC) of ECT, PINP, and β-CTX alone for the diagnosis of bone metastasis of lung cancer were 0.872, 0.888, and 0.874, respectively, and the AUC for the combined diagnosis of the three was 0.963, which was greater than that of any one of the individual indices, with a sensitivity of 86.96% and a specificity of 97.50% at a Youden index of 0.845.

Conclusion: ECT whole-body bone imaging combined with PINP and β-CTX has high diagnostic value for bone metastasis of lung cancer.

研究目的本研究旨在探讨发射计算机断层扫描(ECT)全身骨成像联合 PINP 和 β-CTX 对肺癌骨转移的早期诊断价值:根据有无骨转移将86例肺癌患者的病例资料分为肺癌骨转移组(LCWBM,46例)和肺癌无骨转移组(LCWOBM,40例)。收集患者的一般信息。采用 ECT 全身骨成像检测两组患者的骨转移和疾病范围分级(EOD),并利用电化学发光法检测血清中 PINP 和 β-CTX 的水平。斯皮尔曼相关分析用于评估 EOD 分级与 PINP 和 β-CTX 水平之间的相关性。采用逻辑单变量和多变量回归分析肺癌骨转移的危险因素。应用接收者操作特征曲线(ROC)分析ECT全身骨成像、PINP或β-CTX单项检测及三项检测联合的诊断效果:LCWBM组和LCWOBM组在病理类型、临床分期和EOD分级、ECT阳性例数以及PINP和β-CTX表达水平方面的差异均有统计学意义。在不同ECT分级的LCWBM患者中,PINP和β-CTX的表达趋势为3级>2级>1级和0级。进一步的相关性分析表明,EOD分级与PINP和β-CTX的表达水平呈显著正相关。单变量逻辑回归分析表明,腺癌、TNM IV期、ECT阳性、PINP和β-CTX高表达与肺癌骨转移相关,多变量逻辑回归分析表明,ECT阳性、PINP和β-CTX高表达是肺癌骨转移的独立危险因素。ECT、PINP和β-CTX单独诊断肺癌骨转移的曲线下面积(AUC)分别为0.872、0.888和0.874,三者联合诊断的曲线下面积(AUC)为0.963,大于任何一个单独指标的曲线下面积(AUC),在尤登指数为0.845时,敏感性为86.96%,特异性为97.50%:结论:ECT全身骨成像结合PINP和β-CTX对肺癌骨转移具有较高的诊断价值。
{"title":"Early diagnostic value of ECT whole-body bone imaging combined with PINP and β-CTX for bone metastasis of lung cancer.","authors":"Meiying Jiang, Qiyun Yu, Haitao Mei, Yingchao Jian, Rong Xu","doi":"10.1007/s12094-024-03475-8","DOIUrl":"10.1007/s12094-024-03475-8","url":null,"abstract":"<p><strong>Objective: </strong>This research was aimed at investigating the early diagnostic value of emission computed tomograph (ECT) whole-body bone imaging combined with PINP and β-CTX for bone metastasis of lung cancer.</p><p><strong>Methods: </strong>Case data of 86 lung cancer patients were categorized into lung cancer with bone metastasis (LCWBM, 46 cases) and lung cancer without bone metastasis (LCWOBM, 40 cases) groups according to the presence or absence of bone metastasis. Patients' general information were collected. ECT whole-body bone imaging was used to detect bone metastases and the grading of the extent of disease (EOD) in both groups, and electrochemiluminescence was utilized to detect the serum levels of PINP and β-CTX. Spearman correlation analysis was employed to evaluate the correlation between EOD grading and PINP and β-CTX levels. Logistic univariate and multivariate regression was implemented to analyze the risk factors of bone metastasis of lung cancer. Receiver operating characteristic (ROC) curve was applied to analyze the diagnostic efficacy of the single test of ECT whole-body bone imaging, PINP, or β-CTX and the combination of the three tests.</p><p><strong>Results: </strong>The differences in pathological type, clinical stage and EOD grading, the number of positive ECT cases, and the expression levels of PINP and β-CTX between the LCWBM and LCWOBM groups were statistically significant. In LCWBM patients with different EOD grading, the trends of the expression of PINP and β-CTX were grade 3 > grade 2 > grade 1 and grade 0. Further correlation analyses revealed that EOD grading showed a significant positive correlation with the PINP and β-CTX expression levels. Univariate logistic regression analysis demonstrated that adenocarcinoma, TNM stage IV, ECT positivity, and high expression of PINP and β-CTX were associated with bone metastasis of lung cancer, and multivariate logistic regression analysis indicated that ECT positivity, high expression of PINP and β-CTX were independent risk factors for bone metastasis of lung cancer. The area under the curve (AUC) of ECT, PINP, and β-CTX alone for the diagnosis of bone metastasis of lung cancer were 0.872, 0.888, and 0.874, respectively, and the AUC for the combined diagnosis of the three was 0.963, which was greater than that of any one of the individual indices, with a sensitivity of 86.96% and a specificity of 97.50% at a Youden index of 0.845.</p><p><strong>Conclusion: </strong>ECT whole-body bone imaging combined with PINP and β-CTX has high diagnostic value for bone metastasis of lung cancer.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"3116-3123"},"PeriodicalIF":2.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141176825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Survival analysis in pT1-3 and paracolic lymph-node invasion colorectal cancer: the prognostic role of positive paracolic lymph-node ratio for adjuvant chemotherapy. pT1-3和旁淋巴结侵犯结直肠癌的生存率分析:旁淋巴结阳性率对辅助化疗的预后作用。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-12-01 Epub Date: 2024-05-23 DOI: 10.1007/s12094-024-03470-z
Xiaochuang Feng, Weilin Liao, Yuqing Tang, Xiaojiang Yi, Tieqiao Tian, Hongming Li, Jiaxin Lin, Xinquan Lu, Jin Wan, Jiahao Wang, Haijun Deng, Chuangqi Chen, Dechang Diao

Purpose: Several studies have observed that some stage III colorectal cancer (CRC) patients cannot benefit from standard adjuvant chemotherapy. However, there is no unified screening standard to date.

Methods: Consecutive patients with pathologically confirmed colon adenocarcinoma treated in 3 centers between January 2016 and December 2018 were included. Patients were divided into four groups according to different stages and positive paracolic lymph-node ratio (P-LNR) [Cohort 1: pT1-3N0M0, Cohort 2: pT1-3N + (P-LNR ≤ 0.15)M0, Cohort 3: pT4N0M0, Cohort 4: stage III patients except for pT1-3N + (P-LNR ≤ 0.15)M0], and further overall survival was compared by Kaplan-Meier method. The univariate and multivariate analyses were employed for cox proportional hazards model.

Results: We retrospectively reviewed 5581 consecutive CRC patients with, and 2861 eligible patients were enrolled for further analysis. The optimal cut-off value of P-LNR in our study was 0.15. There was no significant difference in OS (91.36 vs. 93.74%) and DFS (87.65 vs. 90.96%) between stage III patients with pT1-3N + (P-LNR ≤ 0.15)M0 and those with pT1-3N0M0. Further analysis demonstrated that CRC patients with pT1-3N + (P-LNR ≤ 0.15)M0 were less likely to benefit from 8 cycles of CAPOX or FOLFOX chemotherapy and suffered fewer adverse events from declining chemotherapy. Comparing with 0-4 cycles versus 8 cycles, the overall survival rates were 91.35 versus 90.19% (P = 0.79), and with a DFS of 87.50 versus 88.24% (P = 0.49), the duration of adjuvant chemotherapy was not an independent risk factor for patients with pT1-3N + (P-LNR ≤ 0.15)M0 (HR: 0.70, 95% CI 0.90-1.30, P = 0.42).

Conclusion: The concept of P-LNR we proposed might have a high clinical application value and accurately enable clinicians to screen out specific CRC patients who decline or prefer limited chemotherapy.

Trial registry: The clinical trial registration number: ChiCTR2300076883.

目的:多项研究发现,一些 III 期结直肠癌(CRC)患者无法从标准辅助化疗中获益。然而,迄今为止还没有统一的筛查标准:纳入2016年1月至2018年12月期间在3个中心接受治疗的病理确诊结肠腺癌患者。根据不同分期和阳性旁淋巴结比(P-LNR)将患者分为四组[队列1:pT1-3N0M0,队列2:pT1-3N+(P-LNR≤0.15)M0,队列3:pT4N0M0,队列4:除pT1-3N+(P-LNR≤0.15)M0外的III期患者],并采用Kaplan-Meier法进一步比较总生存期。采用cox比例危险度模型进行单变量和多变量分析:我们对 5581 例连续的 CRC 患者进行了回顾性分析,并对 2861 例符合条件的患者进行了进一步分析。在我们的研究中,P-LNR的最佳临界值为0.15。pT1-3N+(P-LNR≤0.15)M0的III期患者与pT1-3N0M0的患者在OS(91.36% vs. 93.74%)和DFS(87.65% vs. 90.96%)方面无明显差异。进一步分析表明,pT1-3N +(P-LNR ≤ 0.15)M0 的 CRC 患者从 8 个周期的 CAPOX 或 FOLFOX 化疗中获益的可能性较小,且因拒绝化疗而发生的不良事件较少。0-4个周期与8个周期相比,总生存率为91.35%对90.19%(P=0.79),DFS为87.50%对88.24%(P=0.49),辅助化疗持续时间不是pT1-3N+(P-LNR≤0.15)M0患者的独立危险因素(HR:0.70,95% CI 0.90-1.30,P=0.42):结论:我们提出的P-LNR概念可能具有较高的临床应用价值,可使临床医生准确筛选出拒绝或倾向于有限化疗的特定CRC患者:临床试验注册号:ChiCTR2300076883ChiCTR2300076883。
{"title":"Survival analysis in pT1-3 and paracolic lymph-node invasion colorectal cancer: the prognostic role of positive paracolic lymph-node ratio for adjuvant chemotherapy.","authors":"Xiaochuang Feng, Weilin Liao, Yuqing Tang, Xiaojiang Yi, Tieqiao Tian, Hongming Li, Jiaxin Lin, Xinquan Lu, Jin Wan, Jiahao Wang, Haijun Deng, Chuangqi Chen, Dechang Diao","doi":"10.1007/s12094-024-03470-z","DOIUrl":"10.1007/s12094-024-03470-z","url":null,"abstract":"<p><strong>Purpose: </strong>Several studies have observed that some stage III colorectal cancer (CRC) patients cannot benefit from standard adjuvant chemotherapy. However, there is no unified screening standard to date.</p><p><strong>Methods: </strong>Consecutive patients with pathologically confirmed colon adenocarcinoma treated in 3 centers between January 2016 and December 2018 were included. Patients were divided into four groups according to different stages and positive paracolic lymph-node ratio (P-LNR) [Cohort 1: pT1-3N0M0, Cohort 2: pT1-3N + (P-LNR ≤ 0.15)M0, Cohort 3: pT4N0M0, Cohort 4: stage III patients except for pT1-3N + (P-LNR ≤ 0.15)M0], and further overall survival was compared by Kaplan-Meier method. The univariate and multivariate analyses were employed for cox proportional hazards model.</p><p><strong>Results: </strong>We retrospectively reviewed 5581 consecutive CRC patients with, and 2861 eligible patients were enrolled for further analysis. The optimal cut-off value of P-LNR in our study was 0.15. There was no significant difference in OS (91.36 vs. 93.74%) and DFS (87.65 vs. 90.96%) between stage III patients with pT1-3N + (P-LNR ≤ 0.15)M0 and those with pT1-3N0M0. Further analysis demonstrated that CRC patients with pT1-3N + (P-LNR ≤ 0.15)M0 were less likely to benefit from 8 cycles of CAPOX or FOLFOX chemotherapy and suffered fewer adverse events from declining chemotherapy. Comparing with 0-4 cycles versus 8 cycles, the overall survival rates were 91.35 versus 90.19% (P = 0.79), and with a DFS of 87.50 versus 88.24% (P = 0.49), the duration of adjuvant chemotherapy was not an independent risk factor for patients with pT1-3N + (P-LNR ≤ 0.15)M0 (HR: 0.70, 95% CI 0.90-1.30, P = 0.42).</p><p><strong>Conclusion: </strong>The concept of P-LNR we proposed might have a high clinical application value and accurately enable clinicians to screen out specific CRC patients who decline or prefer limited chemotherapy.</p><p><strong>Trial registry: </strong>The clinical trial registration number: ChiCTR2300076883.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"2993-3002"},"PeriodicalIF":2.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141089308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ITGB4 is a prognostic biomarker and correlated with lung adenocarcinoma brain metastasis. ITGB4是一种预后生物标志物,与肺腺癌脑转移相关。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-12-01 Epub Date: 2024-05-22 DOI: 10.1007/s12094-024-03527-z
Jingjing Zhang, Lingjie Li, Weiwei Luo, Shenglin Ma, Yanyan Zhao

Background: The aim of this study is to explore the prognostic value and immune signature of ITGB4 expression in lung adenocarcinoma (LUAD) brain metastasis.

Methods: We comprehensively screened genes associated with LUAD brain metastasis by integrating datasets from the GEO database and TMT-based quantitative proteomics profiles. Univariable survival and Multivariate Cox analysis was used to compare several clinical characteristics with survival, and a risk model was constructed. The biological functions were explored via GO and KEGG analysis. Gene set enrichment analysis (GSEA) was performed using the TCGA dataset. In addition, we use TIMER to explore the collection of ITGB4 Expression and Immune Infiltration Level in LUAD. The ability of ITGB4 to regulate tumor metastasis was further assessed by migration, invasion assay and Western-blot in H1975-BrM4 cells.

Results: We found that ITGB4 was the only gene with high clinical diagnostic and prognostic value in LUAD. Enrichment analysis indicated that ITGB4 is associated with brain metastasis, infiltration of immune cells, and the response to immunotherapy. ITGB4 expression can effectively predict the outcomes of patients with LUAD who are receiving anti-PD-1 therapy. ITGB4 knockdown inhibited the invasion, migration of H1975-BrM4 brain metastasis cells, as well as epithelial-mesenchymal transition (EMT) abilities. The heightened expression of ITGB4 protein was shown to promote EMT and enhance the metastatic potential. ITGB4 promotes the progression in H1975-BrM4 cells via MEK/ERK signaling pathway.

Conclusions: Our findings indicate that the expression of ITGB4 is linked to the occurrence of brain metastasis and infiltration of immune cells, suggesting that ITGB4 might be a clinical treatment target for LUAD.

背景:本研究旨在探讨ITGB4在肺腺癌(LUAD)脑转移中的预后价值和免疫特征:本研究旨在探讨ITGB4表达在肺腺癌(LUAD)脑转移中的预后价值和免疫特征:我们通过整合GEO数据库的数据集和基于TMT的定量蛋白质组学图谱,全面筛选了与LUAD脑转移相关的基因。采用单变量生存率和多变量Cox分析比较了几种临床特征与生存率的关系,并构建了风险模型。通过 GO 和 KEGG 分析探讨了生物功能。利用 TCGA 数据集进行了基因组富集分析(GSEA)。此外,我们还利用 TIMER 探索了 LUAD 中 ITGB4 表达和免疫渗透水平的集合。我们还通过迁移、侵袭试验和Western-blot对H1975-BrM4细胞进一步评估了ITGB4调控肿瘤转移的能力:结果:我们发现ITGB4是唯一一个对LUAD具有较高临床诊断和预后价值的基因。富集分析表明,ITGB4与脑转移、免疫细胞浸润和免疫治疗反应有关。ITGB4的表达能有效预测接受抗PD-1治疗的LUAD患者的预后。敲除ITGB4抑制了H1975-BrM4脑转移细胞的侵袭、迁移以及上皮-间质转化(EMT)能力。研究表明,ITGB4 蛋白的高表达可促进 EMT 并增强转移潜能。ITGB4通过MEK/ERK信号通路促进H1975-BrM4细胞的进展:我们的研究结果表明,ITGB4的表达与脑转移的发生和免疫细胞的浸润有关,这表明ITGB4可能是LUAD的临床治疗靶点。
{"title":"ITGB4 is a prognostic biomarker and correlated with lung adenocarcinoma brain metastasis.","authors":"Jingjing Zhang, Lingjie Li, Weiwei Luo, Shenglin Ma, Yanyan Zhao","doi":"10.1007/s12094-024-03527-z","DOIUrl":"10.1007/s12094-024-03527-z","url":null,"abstract":"<p><strong>Background: </strong>The aim of this study is to explore the prognostic value and immune signature of ITGB4 expression in lung adenocarcinoma (LUAD) brain metastasis.</p><p><strong>Methods: </strong>We comprehensively screened genes associated with LUAD brain metastasis by integrating datasets from the GEO database and TMT-based quantitative proteomics profiles. Univariable survival and Multivariate Cox analysis was used to compare several clinical characteristics with survival, and a risk model was constructed. The biological functions were explored via GO and KEGG analysis. Gene set enrichment analysis (GSEA) was performed using the TCGA dataset. In addition, we use TIMER to explore the collection of ITGB4 Expression and Immune Infiltration Level in LUAD. The ability of ITGB4 to regulate tumor metastasis was further assessed by migration, invasion assay and Western-blot in H1975-BrM4 cells.</p><p><strong>Results: </strong>We found that ITGB4 was the only gene with high clinical diagnostic and prognostic value in LUAD. Enrichment analysis indicated that ITGB4 is associated with brain metastasis, infiltration of immune cells, and the response to immunotherapy. ITGB4 expression can effectively predict the outcomes of patients with LUAD who are receiving anti-PD-1 therapy. ITGB4 knockdown inhibited the invasion, migration of H1975-BrM4 brain metastasis cells, as well as epithelial-mesenchymal transition (EMT) abilities. The heightened expression of ITGB4 protein was shown to promote EMT and enhance the metastatic potential. ITGB4 promotes the progression in H1975-BrM4 cells via MEK/ERK signaling pathway.</p><p><strong>Conclusions: </strong>Our findings indicate that the expression of ITGB4 is linked to the occurrence of brain metastasis and infiltration of immune cells, suggesting that ITGB4 might be a clinical treatment target for LUAD.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"2979-2992"},"PeriodicalIF":2.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141077255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MKI67 with arterial hypertension predict a poor survival for prostate cancer patients, a real-life investigation. MKI67 伴有动脉高血压可预测前列腺癌患者的不良生存率,这是一项现实生活调查。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-12-01 Epub Date: 2024-05-24 DOI: 10.1007/s12094-024-03505-5
Yongqiang Zhou, Weihai Chen, Hao Jiang, Yuke Zhang, Zheng Ma, Zhenfan Wang, Chen Xu, Minjun Jiang, Jianchun Chen, Zhijun Cao

Introduction: Prostate cancer is a common urology malignant in males, ranking second globally. The disease is especially severe when diagnosed alongside hypertension. MKI67 is an established marker of neoplastic cell proliferation in humans, but the significance of its prognostic value in patients with prostate cancer and hypertension requires further research.

Methods: In this retrospective analysis, we evaluated 296 hypertensive prostate cancer patients between March 2, 2012, and November 1, 2015. We used Cox regression models and prediction analysis to assess overall survival. Furthermore, we created a nomogram and verified its accuracy using a calibration curve.

Results: Of all participants, 101 (34.12%) died. Our multi-factor analysis revealed that MKI67 expression was associated with an increased hazard ratio of death (> fivefold) (Hazard Ratio 5.829, 95% CI 3.349-10.138, p value < 0.01) and progression (twofold) (HR 2.059, 95% CI 1.368-3.102, p value < 0.01). Our Lasso analysis model displayed that several factors, including heart failure, smoking, ACS, serum albumin, Gealson score, prognostic nutritional index, MKI67 expression, surgery, and stage were high risks of prostate cancer. To ensure each covariate's contribution to cancer prognosis, we created a Cox model nomogram, which accurately predicted the risk of death (C-statistic of 0.8289) and had a proper calibration plot for risk assessment.

Conclusion: MKI67 expression predicts poor outcomes for overall mortality in prostate cancer and hypertension patients. Additionally, our cross-validated multivariate score, which includes MKI67, demonstrated accuracy efficacy of predicting prognosis.

简介前列腺癌是男性常见的泌尿科恶性肿瘤,在全球排名第二。如果同时被诊断出患有高血压,病情将尤为严重。MKI67 是人类肿瘤细胞增殖的既定标志物,但其在前列腺癌和高血压患者中的预后价值还需要进一步研究:在这项回顾性分析中,我们对 2012 年 3 月 2 日至 2015 年 11 月 1 日期间的 296 名高血压前列腺癌患者进行了评估。我们使用 Cox 回归模型和预测分析来评估总生存率。此外,我们还创建了一个提名图,并使用校准曲线验证了其准确性:在所有参与者中,101 人(34.12%)死亡。我们的多因素分析表明,MKI67 的表达与死亡危险比增加(> 5 倍)有关(危险比 5.829,95% CI 3.349-10.138,P 值 结论:MKI67 的表达可预测患者的不良生存状况:MKI67的表达可预测前列腺癌和高血压患者的总死亡率。此外,我们的交叉验证多变量评分(包括 MKI67)显示了预测预后的准确性。
{"title":"MKI67 with arterial hypertension predict a poor survival for prostate cancer patients, a real-life investigation.","authors":"Yongqiang Zhou, Weihai Chen, Hao Jiang, Yuke Zhang, Zheng Ma, Zhenfan Wang, Chen Xu, Minjun Jiang, Jianchun Chen, Zhijun Cao","doi":"10.1007/s12094-024-03505-5","DOIUrl":"10.1007/s12094-024-03505-5","url":null,"abstract":"<p><strong>Introduction: </strong>Prostate cancer is a common urology malignant in males, ranking second globally. The disease is especially severe when diagnosed alongside hypertension. MKI67 is an established marker of neoplastic cell proliferation in humans, but the significance of its prognostic value in patients with prostate cancer and hypertension requires further research.</p><p><strong>Methods: </strong>In this retrospective analysis, we evaluated 296 hypertensive prostate cancer patients between March 2, 2012, and November 1, 2015. We used Cox regression models and prediction analysis to assess overall survival. Furthermore, we created a nomogram and verified its accuracy using a calibration curve.</p><p><strong>Results: </strong>Of all participants, 101 (34.12%) died. Our multi-factor analysis revealed that MKI67 expression was associated with an increased hazard ratio of death (> fivefold) (Hazard Ratio 5.829, 95% CI 3.349-10.138, p value < 0.01) and progression (twofold) (HR 2.059, 95% CI 1.368-3.102, p value < 0.01). Our Lasso analysis model displayed that several factors, including heart failure, smoking, ACS, serum albumin, Gealson score, prognostic nutritional index, MKI67 expression, surgery, and stage were high risks of prostate cancer. To ensure each covariate's contribution to cancer prognosis, we created a Cox model nomogram, which accurately predicted the risk of death (C-statistic of 0.8289) and had a proper calibration plot for risk assessment.</p><p><strong>Conclusion: </strong>MKI67 expression predicts poor outcomes for overall mortality in prostate cancer and hypertension patients. Additionally, our cross-validated multivariate score, which includes MKI67, demonstrated accuracy efficacy of predicting prognosis.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"3037-3049"},"PeriodicalIF":2.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141094409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of IGF/IGF-1R signaling in the regulation of cancer stem cells. IGF/IGF-1R 信号在调节癌症干细胞中的作用。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-12-01 Epub Date: 2024-06-12 DOI: 10.1007/s12094-024-03561-x
Fengchao Liu, Susu Ye, Liu Zhao, Qinghui Niu

Cancer stem cells (CSCs) are a group of tumor cells with high tumorigenic ability and self-renewal potential similar to those of normal stem cells. CSCs are the key "seeds" for tumor development, metastasis, and recurrence. A better insight into the key mechanisms underlying CSC survival improves the efficiency of cancer therapy via specific targeting of CSCs. Insulin-like growth factor (IGF)/IGF-1 receptor (IGF-1R) signaling plays an important role in the maintenance of cancer stemness. However, the effect of IGF/IGF-1R signaling on stemness and CSCs and the underlying mechanisms are still controversial. Based on the similarity between CSCs and normal stem cells, this review discusses emerging data on the functions of IGF/IGF-1R signaling in normal stem cells and CSCs and dissects the underlying mechanisms by which IGF/IGF-1R signaling is involved in CSCs. On the other hand, this review highlighted the role of IGF/IGF-1R signaling blockade in multiple CSCs as a potential strategy to improve CSC-based therapy.

癌症干细胞(CSCs)是一类具有高度致瘤能力和自我更新潜能的肿瘤细胞,与正常干细胞相似。癌症干细胞是肿瘤发生、转移和复发的关键 "种子"。深入了解 CSC 存活的关键机制,可以通过特异性靶向 CSC 提高癌症治疗的效率。胰岛素样生长因子(IGF)/IGF-1受体(IGF-1R)信号在维持癌症干细胞中发挥着重要作用。然而,IGF/IGF-1R 信号对干性和 CSCs 的影响及其内在机制仍存在争议。基于CSCs与正常干细胞的相似性,本综述讨论了正常干细胞和CSCs中IGF/IGF-1R信号转导功能的新数据,并剖析了IGF/IGF-1R信号转导参与CSCs的内在机制。另一方面,这篇综述强调了阻断IGF/IGF-1R信号在多种CSCs中的作用,以此作为改善基于CSC疗法的潜在策略。
{"title":"The role of IGF/IGF-1R signaling in the regulation of cancer stem cells.","authors":"Fengchao Liu, Susu Ye, Liu Zhao, Qinghui Niu","doi":"10.1007/s12094-024-03561-x","DOIUrl":"10.1007/s12094-024-03561-x","url":null,"abstract":"<p><p>Cancer stem cells (CSCs) are a group of tumor cells with high tumorigenic ability and self-renewal potential similar to those of normal stem cells. CSCs are the key \"seeds\" for tumor development, metastasis, and recurrence. A better insight into the key mechanisms underlying CSC survival improves the efficiency of cancer therapy via specific targeting of CSCs. Insulin-like growth factor (IGF)/IGF-1 receptor (IGF-1R) signaling plays an important role in the maintenance of cancer stemness. However, the effect of IGF/IGF-1R signaling on stemness and CSCs and the underlying mechanisms are still controversial. Based on the similarity between CSCs and normal stem cells, this review discusses emerging data on the functions of IGF/IGF-1R signaling in normal stem cells and CSCs and dissects the underlying mechanisms by which IGF/IGF-1R signaling is involved in CSCs. On the other hand, this review highlighted the role of IGF/IGF-1R signaling blockade in multiple CSCs as a potential strategy to improve CSC-based therapy.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"2924-2934"},"PeriodicalIF":2.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141307260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Different genetic profiles contribute to worse overall survival in patients with leptomeningeal metastases of non-small-cell lung cancer. 不同的遗传特征导致非小细胞肺癌脑膜转移患者的总生存率降低。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-12-01 Epub Date: 2024-05-25 DOI: 10.1007/s12094-024-03507-3
Xusheng Tang, Xiaojuan Hu, Lin Yuan, Hainan Yang, Yunfen Luo, Da Liu, Qingjun Hu, Changguo Shan, Tao Lin, Linbo Cai, Zhaoming Zhou, Xin Jin, Ming Lei, Weiping Hong

Background: To assess the genetic characteristics of central nervous system (CNS) metastases from non-small-cell lung cancer (NSCLC), we gathered the genetic profiles of brain metastases (BM) and leptomeningeal metastases (LM). Our objective was to identify genetic factors contributing to poorer overall survival (OS) in NSCLC patients with LM.

Methods: This study included 25 consecutive patients with BM and 52 patients with LM from Guangdong Sanjiu Brain Hospital. All participants underwent 168-target panel sequencing.

Results: Among the 25 patients with BM, TP53 was the most frequently mutated gene (44%), followed by driver genes such as EGFR and BRAF (40% and 20%, respectively). In patients with BM, EGFR_amp and CDK4 were also frequently mutated, with rates of 20% and 16%, respectively. The genetic landscape of patients with LM differed, with the top mutated genes being EGFR, TP53, EGFR_amp, CDKN2A, CCNE1, CDK4, PMS2, and PIK3CA, with mutation rates of 77%, 69%, 31%, 29%, 13%, 13%, 13%, and 12%, respectively. In our study, patients with LM exhibited significantly worse OS compared to those with BM (p = 0.029). The mutation rates of TP53, EGFR_amp, and CDKN2A varied between patients with LM and those with BM, at 69.23% vs. 44%, 30.77% vs. 20%, and 28.85% vs. 12%, respectively. Further exploration revealed that patients with BM with TP53 mutations had a shorter OS than patients without TP53 mutations (p = 0.014). Similarly, patients with LM and TP53 mutations presented with worse OS than those without TP53 mutations (p = 0.0067). LM patients with CDKN2A deletions had worse OS than those without CDKN2A deletions (p = 0.037). Additionally, patients with EGFR_amp had a shorter OS than those without EGFR_amp (p = 0.044).

Conclusions: Patients with LM exhibited significantly worse OS than those with BM. Gene signatures, such as TP53, EGFR_amp, and CDKN2A, may account for shorter outcomes in patients with LM.

背景:为了评估非小细胞肺癌(NSCLC)中枢神经系统(CNS)转移灶的遗传特征,我们收集了脑转移灶(BM)和钩端膜转移灶(LM)的遗传特征。我们的目的是找出导致NSCLC脑转移瘤患者总生存期(OS)较差的遗传因素:本研究纳入了广东三九脑科医院的25例连续性BM患者和52例LM患者。所有参与者均接受了168个靶点的面板测序:结果:在25名BM患者中,TP53是最常见的突变基因(44%),其次是EGFR和BRAF等驱动基因(分别为40%和20%)。在骨髓瘤患者中,表皮生长因子受体_amp和CDK4也经常发生突变,突变率分别为20%和16%。LM患者的基因情况有所不同,突变率最高的基因是表皮生长因子受体、TP53、表皮生长因子受体_amp、CDKN2A、CCNE1、CDK4、PMS2和PIK3CA,突变率分别为77%、69%、31%、29%、13%、13%、13%和12%。在我们的研究中,LM 患者的 OS 明显低于 BM 患者(P = 0.029)。LM患者和BM患者的TP53、EGFR_amp和CDKN2A突变率不同,分别为69.23%对44%、30.77%对20%和28.85%对12%。进一步研究发现,TP53突变的BM患者的OS短于无TP53突变的患者(P = 0.014)。同样,LM和TP53突变患者的OS也比没有TP53突变的患者差(p = 0.0067)。CDKN2A缺失的LM患者的OS比没有CDKN2A缺失的患者更差(p = 0.037)。此外,EGFR_amp患者的OS短于无EGFR_amp的患者(p = 0.044):结论:LM 患者的 OS 明显差于 BM 患者。TP53、表皮生长因子受体_amp和CDKN2A等基因特征可能是导致LM患者预后较短的原因。
{"title":"Different genetic profiles contribute to worse overall survival in patients with leptomeningeal metastases of non-small-cell lung cancer.","authors":"Xusheng Tang, Xiaojuan Hu, Lin Yuan, Hainan Yang, Yunfen Luo, Da Liu, Qingjun Hu, Changguo Shan, Tao Lin, Linbo Cai, Zhaoming Zhou, Xin Jin, Ming Lei, Weiping Hong","doi":"10.1007/s12094-024-03507-3","DOIUrl":"10.1007/s12094-024-03507-3","url":null,"abstract":"<p><strong>Background: </strong>To assess the genetic characteristics of central nervous system (CNS) metastases from non-small-cell lung cancer (NSCLC), we gathered the genetic profiles of brain metastases (BM) and leptomeningeal metastases (LM). Our objective was to identify genetic factors contributing to poorer overall survival (OS) in NSCLC patients with LM.</p><p><strong>Methods: </strong>This study included 25 consecutive patients with BM and 52 patients with LM from Guangdong Sanjiu Brain Hospital. All participants underwent 168-target panel sequencing.</p><p><strong>Results: </strong>Among the 25 patients with BM, TP53 was the most frequently mutated gene (44%), followed by driver genes such as EGFR and BRAF (40% and 20%, respectively). In patients with BM, EGFR_amp and CDK4 were also frequently mutated, with rates of 20% and 16%, respectively. The genetic landscape of patients with LM differed, with the top mutated genes being EGFR, TP53, EGFR_amp, CDKN2A, CCNE1, CDK4, PMS2, and PIK3CA, with mutation rates of 77%, 69%, 31%, 29%, 13%, 13%, 13%, and 12%, respectively. In our study, patients with LM exhibited significantly worse OS compared to those with BM (p = 0.029). The mutation rates of TP53, EGFR_amp, and CDKN2A varied between patients with LM and those with BM, at 69.23% vs. 44%, 30.77% vs. 20%, and 28.85% vs. 12%, respectively. Further exploration revealed that patients with BM with TP53 mutations had a shorter OS than patients without TP53 mutations (p = 0.014). Similarly, patients with LM and TP53 mutations presented with worse OS than those without TP53 mutations (p = 0.0067). LM patients with CDKN2A deletions had worse OS than those without CDKN2A deletions (p = 0.037). Additionally, patients with EGFR_amp had a shorter OS than those without EGFR_amp (p = 0.044).</p><p><strong>Conclusions: </strong>Patients with LM exhibited significantly worse OS than those with BM. Gene signatures, such as TP53, EGFR_amp, and CDKN2A, may account for shorter outcomes in patients with LM.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"3058-3064"},"PeriodicalIF":2.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141097250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advanced non-squamous NSCLC with no actionable oncogenic driver in Spain: a cross-sectional descriptive analysis of data from the Thoracic Tumor Registry. 西班牙无可操作性致癌驱动因素的晚期非鳞状 NSCLC:胸部肿瘤登记处数据的横断面描述性分析。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-12-01 Epub Date: 2024-06-11 DOI: 10.1007/s12094-024-03511-7
Enric Carcereny, Delvys Rodriguez-Abreu, Rafael Lopez, Fabio Franco, Maria Guirado, Bartomeu Massutí, Manuel Cobo, Ana Blasco, Guillermo Suay, Edel Del Barco, Ana Laura Ortega, Maria Angeles Sala, Patricia Cordeiro, Reyes Bernabé, José Luís González Larriba, Joaquim Bosch-Barrera, Julia Calzas, Joaquín Casal, Airam Padilla, Alfredo Sánchez-Hernandez, Mariano Provencio

Background: Non-small cell lung cancer (NSCLC) accounts for the vast majority of all diagnosed lung cancers. According to their histology, most NSCLCs are considered non-squamous cell carcinoma (NSCC), and up to 85% of the latter may lack either one of the two main actionable oncogenic drivers (i.e., EGFR mutations and ALK rearrangements).

Objective: Our analysis aimed to describe the clinical and epidemiological characteristics of Spanish patients suffering from NSCC with no actionable oncogenic driver in daily clinical practice.

Design: A retrospective, cross-sectional, descriptive analysis.

Methods: We analyzed the records of all Spanish patients with advanced NSCC diagnosed between January 2011 and January 2020 and included in the Spanish Thoracic Tumor Registry database. We evaluated the presence of metastasis and molecular profiling at the time of diagnosis and treatments received. We also assessed overall survival (OS) and progression-free survival (PFS) according to first-line treatment.

Results: One thousand seven hundred ninety-seven Spanish patients with NSCC were included. They were mainly men (73.2%), smokers (current [44.4%] and former [44.4%]) and presented adenocarcinoma histology (97.6%). Most patients had at least one comorbidity (80.4%) and one metastatic site (96.8%), and a non-negligible number of those tested were PD-L1 positive (35.2%). Notably, the presence of liver metastasis indicated a shorter median OS and PFS than metastasis in other locations (p < 0.001). Chemotherapy was more often prescribed than immunotherapy as first-, second-, and third-line treatment in that period. In first-line, the OS rates were similar in patients receiving either regimen, but PFS rates significantly better in patients treated with immunotherapy (p = 0.026). Also, a high number of patients did not reach second- and third-line treatment, suggesting the failure of current early diagnostic measures and therapies.

Conclusions: This analysis of the most lethal tumor in Spain could highlight the strengths and the weaknesses of its clinical management and set the ground for further advances and research.

背景:非小细胞肺癌(NSCLC非小细胞肺癌(NSCLC)占所有确诊肺癌的绝大多数。根据其组织学,大多数非小细胞肺癌被认为是非鳞状细胞癌(NSCC),其中高达 85% 的非小细胞肺癌可能缺乏两种主要致癌驱动因素(即表皮生长因子受体突变和 ALK 重排)中的一种:我们的分析旨在描述日常临床实践中无可作用致癌因素的西班牙 NSCC 患者的临床和流行病学特征:设计:回顾性、横断面、描述性分析:我们分析了 2011 年 1 月至 2020 年 1 月期间确诊并纳入西班牙胸部肿瘤登记数据库的所有西班牙晚期 NSCC 患者的记录。我们评估了诊断时的转移情况和分子特征以及接受的治疗。我们还根据一线治疗情况评估了总生存期(OS)和无进展生存期(PFS):共纳入1797名西班牙NSCC患者。他们主要为男性(73.2%)、吸烟者(目前吸烟者[44.4%]和曾经吸烟者[44.4%]),组织学表现为腺癌(97.6%)。大多数患者至少有一种合并症(80.4%)和一个转移部位(96.8%),接受检测的患者中,PD-L1 阳性者的比例也不容忽视(35.2%)。值得注意的是,与其他部位的转移相比,出现肝脏转移表明中位OS和PFS更短(P 结论:肝脏转移的患者中位OS和PFS更短(P 结论:肝脏转移的患者中位OS和PFS更短(P 结论):这项对西班牙致死率最高的肿瘤的分析可以突出其临床管理的优势和不足,为进一步的进展和研究奠定基础。
{"title":"Advanced non-squamous NSCLC with no actionable oncogenic driver in Spain: a cross-sectional descriptive analysis of data from the Thoracic Tumor Registry.","authors":"Enric Carcereny, Delvys Rodriguez-Abreu, Rafael Lopez, Fabio Franco, Maria Guirado, Bartomeu Massutí, Manuel Cobo, Ana Blasco, Guillermo Suay, Edel Del Barco, Ana Laura Ortega, Maria Angeles Sala, Patricia Cordeiro, Reyes Bernabé, José Luís González Larriba, Joaquim Bosch-Barrera, Julia Calzas, Joaquín Casal, Airam Padilla, Alfredo Sánchez-Hernandez, Mariano Provencio","doi":"10.1007/s12094-024-03511-7","DOIUrl":"10.1007/s12094-024-03511-7","url":null,"abstract":"<p><strong>Background: </strong>Non-small cell lung cancer (NSCLC) accounts for the vast majority of all diagnosed lung cancers. According to their histology, most NSCLCs are considered non-squamous cell carcinoma (NSCC), and up to 85% of the latter may lack either one of the two main actionable oncogenic drivers (i.e., EGFR mutations and ALK rearrangements).</p><p><strong>Objective: </strong>Our analysis aimed to describe the clinical and epidemiological characteristics of Spanish patients suffering from NSCC with no actionable oncogenic driver in daily clinical practice.</p><p><strong>Design: </strong>A retrospective, cross-sectional, descriptive analysis.</p><p><strong>Methods: </strong>We analyzed the records of all Spanish patients with advanced NSCC diagnosed between January 2011 and January 2020 and included in the Spanish Thoracic Tumor Registry database. We evaluated the presence of metastasis and molecular profiling at the time of diagnosis and treatments received. We also assessed overall survival (OS) and progression-free survival (PFS) according to first-line treatment.</p><p><strong>Results: </strong>One thousand seven hundred ninety-seven Spanish patients with NSCC were included. They were mainly men (73.2%), smokers (current [44.4%] and former [44.4%]) and presented adenocarcinoma histology (97.6%). Most patients had at least one comorbidity (80.4%) and one metastatic site (96.8%), and a non-negligible number of those tested were PD-L1 positive (35.2%). Notably, the presence of liver metastasis indicated a shorter median OS and PFS than metastasis in other locations (p < 0.001). Chemotherapy was more often prescribed than immunotherapy as first-, second-, and third-line treatment in that period. In first-line, the OS rates were similar in patients receiving either regimen, but PFS rates significantly better in patients treated with immunotherapy (p = 0.026). Also, a high number of patients did not reach second- and third-line treatment, suggesting the failure of current early diagnostic measures and therapies.</p><p><strong>Conclusions: </strong>This analysis of the most lethal tumor in Spain could highlight the strengths and the weaknesses of its clinical management and set the ground for further advances and research.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"3218-3225"},"PeriodicalIF":2.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141307259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pyrotinib as a salvage treatment for patients with HER-2 positive advanced lung adenocarcinoma after the progression of afatinib treatment. 派罗替尼作为HER-2阳性晚期肺腺癌患者在阿法替尼治疗进展后的一种挽救性治疗方法。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-12-01 Epub Date: 2024-05-25 DOI: 10.1007/s12094-024-03482-9
Manyi Xu, Yanhua Wang, Keda Shao, Yue Hao, Zhengbo Song

Background: The efficacy of afatinib or pyrotinib has been demonstrated in HER2-positive advanced non-small cell lung cancer (NSCLC) patients; however, the efficacy of pyrotinib after afatinib progression has yet to be determined.

Method: Patients with HER2 mutated advanced lung adenocarcinoma administered afatinib or pyrotinib monotherapy were enrolled. Those who received pyrotinib after afatinib were further analyzed to determine the efficacy and safety of pyrotinib after progression on afatinib. Survival curves were plotted with the Kaplan-Meier method. A swimming plot was used to describe the specific treatments. Additionally, patient-derived tumor organoids (PDTOs) were established from HER2-amplified NSCLC patient samples to investigate the antitumor activity of pyrotinib in HER2-amplified tumor cells in vitro.

Results: A total of 99 patients were enrolled, 13 of whom were administered pyrotinib after progression on afatinib. No statistical difference in PFS of pyrotinib was observed between patients whether be treated after afatinib progression or not (6.7 months vs. 4.4 months, P = 0.817), thus indicating that progression on afatinib did not affect the efficacy of pyrotinib. Further analysis was conducted on the former patients, which comprising eight patients administered interval chemotherapy after progression on afatinib. Two patients achieved PR after pyrotinib treatment. No independent factors were found to influence the PFS of pyrotinib. PDTOs confirmed the anti-tumor activity of pyrotinib in NSCLC tumor cells with HER2 amplification.

Conclusions: Progression after prior afatinib treatment does not influence the efficacy of pyrotinib treatment. Pyrotinib may be a salvage option for patients with HER2 mutation who have experienced progression on afatinib.

背景:阿法替尼或吡罗替尼对HER2阳性晚期非小细胞肺癌(NSCLC)患者的疗效已得到证实;然而,阿法替尼治疗进展后吡罗替尼的疗效尚未确定:方法:研究人员招募了接受阿法替尼或派罗替尼单药治疗的HER2突变晚期肺腺癌患者。对阿法替尼治疗后接受吡罗替尼治疗的患者进行进一步分析,以确定阿法替尼治疗进展后吡罗替尼的疗效和安全性。采用 Kaplan-Meier 法绘制生存曲线。游泳图用于描述特定的治疗方法。此外,还从HER2扩增的NSCLC患者样本中建立了患者衍生肿瘤器官组织(PDTOs),以研究吡罗替尼在体外HER2扩增肿瘤细胞中的抗肿瘤活性:共有99名患者入组,其中13名患者在阿法替尼治疗进展后接受了吡罗替尼治疗。阿法替尼治疗进展与否的患者服用吡罗替尼的PFS无统计学差异(6.7个月 vs. 4.4个月,P = 0.817),这表明阿法替尼治疗进展不影响吡罗替尼的疗效。进一步的分析是针对阿法替尼治疗进展后接受间歇化疗的前患者,其中包括8名患者。有两名患者在接受了吡罗替尼治疗后获得了PR。没有发现影响派罗替尼 PFS 的独立因素。PDTOs证实了派罗替尼在HER2扩增的NSCLC肿瘤细胞中的抗肿瘤活性:结论:先前阿法替尼治疗后的病情进展不会影响派罗替尼的疗效。对于阿法替尼治疗后出现进展的HER2突变患者,派罗替尼可能是一种挽救选择。
{"title":"Pyrotinib as a salvage treatment for patients with HER-2 positive advanced lung adenocarcinoma after the progression of afatinib treatment.","authors":"Manyi Xu, Yanhua Wang, Keda Shao, Yue Hao, Zhengbo Song","doi":"10.1007/s12094-024-03482-9","DOIUrl":"10.1007/s12094-024-03482-9","url":null,"abstract":"<p><strong>Background: </strong>The efficacy of afatinib or pyrotinib has been demonstrated in HER2-positive advanced non-small cell lung cancer (NSCLC) patients; however, the efficacy of pyrotinib after afatinib progression has yet to be determined.</p><p><strong>Method: </strong>Patients with HER2 mutated advanced lung adenocarcinoma administered afatinib or pyrotinib monotherapy were enrolled. Those who received pyrotinib after afatinib were further analyzed to determine the efficacy and safety of pyrotinib after progression on afatinib. Survival curves were plotted with the Kaplan-Meier method. A swimming plot was used to describe the specific treatments. Additionally, patient-derived tumor organoids (PDTOs) were established from HER2-amplified NSCLC patient samples to investigate the antitumor activity of pyrotinib in HER2-amplified tumor cells in vitro.</p><p><strong>Results: </strong>A total of 99 patients were enrolled, 13 of whom were administered pyrotinib after progression on afatinib. No statistical difference in PFS of pyrotinib was observed between patients whether be treated after afatinib progression or not (6.7 months vs. 4.4 months, P = 0.817), thus indicating that progression on afatinib did not affect the efficacy of pyrotinib. Further analysis was conducted on the former patients, which comprising eight patients administered interval chemotherapy after progression on afatinib. Two patients achieved PR after pyrotinib treatment. No independent factors were found to influence the PFS of pyrotinib. PDTOs confirmed the anti-tumor activity of pyrotinib in NSCLC tumor cells with HER2 amplification.</p><p><strong>Conclusions: </strong>Progression after prior afatinib treatment does not influence the efficacy of pyrotinib treatment. Pyrotinib may be a salvage option for patients with HER2 mutation who have experienced progression on afatinib.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"3050-3057"},"PeriodicalIF":2.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141096809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Clinical & Translational Oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1